CHU Brugmann
Brussels, 1020, Belgium
NCT Number: NCT03918824
Coronary heart disease remains one of the main causes of death in the world. One of the treatments for coronary heart disease is percutaneous coronary intervention (PCI). This requires the arterial administration of iodinated contrast medium (ICP) to visualize the state of the coronary arteries and possibly apply the treatment.
For the vast majority of the population, exposure to ICP is perfectly well tolerated. Nevertheless, some complications can occur including a nephropathy induced by the injection of a contrast product (NIC). NIC is the third cause of an acquired acute renal failure within the hospital.It significantly increases morbidity and mortality and prolongs the hospital stay.
Of all the procedures requiring ICP administration, PCI is associated with the highest rate of NIC.This evidence is explained by the fact that patients benefiting from such exploration have a higher risk profile in terms of cardiovascular comorbidities and associated pathologies.Age, preexisting alteration of renal function, diabetes mellitus, polypharmacy, congestive heart failure, type and volume of iodinated contrast medium are the main risk factors for developing NIC.
Nowadays, the use of PCI in the assessment of coronary heart disease in patients with these risk factors is becoming more frequent. This is linked to the aging of the population and the increasing incidence of cardiovascular diseases.
ICP-induced nephrotoxicity results from two main phenomena: the renal medullary hypoxia caused by the vasoconstriction of peritubular capillaries and a direct cytotoxicity towards tubular epithelial cells.These intra-renal mechanisms lead to an acute renal function impairment.NIC is defined as an increase of serum creatinemia ≥ 0.5 mg / dL (or a 25% increase) from the baseline in the 48-72h following PC injection with no other obvious etiology. It reaches its peak between the 3rd and 5th day with a resolution in 10 to 21 days.
The prevention of NIC based primarily on the identification of patients at risk and the use of pharmacological means (as hydration protocol). In contrast, there is little data on the relationship between NIC and the PCI volume used. To the investigator's knowledge, the threshold of toxic volume is not well defined. Taking into account these elements, the investigators propose to study the relation between the volume of iodinated contrast product injected during an ICP and the occurrence of a NIC according to the criteria mentioned above.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Brussels, 1020, Belgium
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
None
Data extraction from medical files
Time frame: 7 years
incidence of nephropathy induced by injection of contrast medium
Time frame: 1 day
Volume of iodinated contrast medium injected
Time frame: 1 day
Body mass
Time frame: 10 days after PCI
Urea concentration
Time frame: 10 days after PCI
Creatinin rate
Time frame: 10 days after PCI
Glomerular filtration rate
Time frame: 7 years
Existence of at least one of these risk factors: diabetes mellitus, abnormal blood pressure, abnormal kidney function, congestive heart failure.
Time frame: Baseline (day of percutaneous coronary intervention (PCI))
Urea concentration
Time frame: 24 hours after of PCI
Urea concentration
Time frame: 48 hours after PCI
Urea concentration
Time frame: 72 hours after PCI
Urea concentration
Time frame: 21 days after PCI
Urea concentration
Time frame: 1 year after PCI
Urea concentration
Time frame: Baseline (day of percutaneous coronary intervention (PCI))
Creatinin rate
Time frame: 24 hours after of PCI
Creatinin rate
Time frame: 48 hours after PCI
Creatinin rate
Time frame: 72 hours after PCI
Creatinin rate
Time frame: 21 days after PCI
Creatinin rate
Time frame: 1 year after PCI
Creatinin rate
Time frame: Baseline (day of percutaneous coronary intervention (PCI))
Glomerular filtration rate
Time frame: 24 hours after of PCI
Glomerular filtration rate
Time frame: 48 hours after PCI
Glomerular filtration rate
Time frame: 72 hours after PCI
Glomerular filtration rate
Time frame: 21 days after PCI
Glomerular filtration rate
Time frame: 1 year after PCI
Glomerular filtration rate
Agnieszka Pozdzik
Other
Retrospective Analysis of the Influence of Iodinated Contrast Volume Injected During Coronarography on Contrast Nephropathy.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03719339
Acute Cellular Graft Rejection, Antibody-mediated Rejection
La Jolla, California, United States
View Trial DetailsNCT03620773
Adolescent Obesity, Bariatric Surgery Candidate
Aurora, Colorado, United States
View Trial DetailsNCT06806644
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Bologna, Italy
View Trial DetailsNCT02675686
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Amiens, France
View Trial Details